Navigation Links
Studies Show Effect of BYDUREON™ on A1C and Weight for Up to Three Years
Date:6/24/2011

atients in their efforts to achieve and sustain glycemic control.(vi,vii)

About BYETTA® (exenatide) injection

BYETTA was the first glucagon-like peptide-1 (GLP-1) receptor agonist to be approved by the FDA for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone GLP-1. GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain.

BYETTA is an injectable prescription medicine that may improve blood sugar (glucose) control in adults with type 2 diabetes mellitus, when used with a diet and exercise program. BYETTA is not insulin and should not be taken instead of insulin. BYETTA is not currently recommended to be taken with insulin. BYETTA is not for people with type 1 diabetes or people with diabetic ketoacidosis. BYETTA has not been studied in people who have pancreatitis.

BYETTA provides sustained A1C control and low incidence of hypoglycemia when used alone or in combination with metformin or a thiazolidinedione, with potential weight loss (BYETTA is not a weight-loss product). BYETTA was approved in the U.S. in April 2005 and in Europe in November 2006 and has been used by more than 1.8 million patients since its introduction. See important safety information below. Additional information about BYETTA is available at www.BYETTA.com.

Important Safety Information for BYETTA® (exenatide) injection

Based on postmarketing data BYETTA has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. Patients should be observed for signs and symptoms of pancreatitis after initiation or dose escalation of BYETTA. The risk for getting low blood sugar is higher if BYETTA is taken with another medicine that can cause low blood sugar, such as a sulfonylurea. BYETTA should not be used in people who ha
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
2. Best of ASCO Features Two Studies Led by US Oncology Research Affiliated Physicians
3. Data from Clinical Studies of bioTheranostics CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting
4. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
5. Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
6. Additional Data From Multiple Phase 1 and 2 Studies of S*BIOs Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
7. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
8. Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
9. Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO
10. New Studies Support CardioFocus HeartLight™ Endoscopic Ablation Systems Notable Treatment Results for Paroxysmal Atrial Fibrillation
11. Esperion Announces Results From Phase 1 Study and Four Preclinical Studies for ETC-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Veran ... company, announced today the positive, cost-effective final ... innovative SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous ... a percutaneous approach to biopsy when a ... patients and physicians experience positive financial outcomes ...
(Date:7/11/2014)... , July 11, 2014 Neurelis, Inc. ("Neurelis") ... to end the option held by Biotie to purchase ... development of NRL-1 (intranasal diazepam) for pediatric and adult ... Over the past year, Biotie has advanced the development ... for the pivotal clinical work required for NDA submission ...
(Date:7/10/2014)... , 11. Juli 2014  Dilon ... für die molekulare Bildgebung, einschließlich molekularer ... die CE-Zulassung für sein Navigator ® ... Dilon das Produkt jetzt europaweit vertreiben. ... Großteil der europäischen Länder ausgedehnt und ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... Oct. 18 Findings from the PRECiSE 3 (P3) ... demonstrating the longest continuously running maintenance trial for an ... 2010 Annual Scientific Meeting of the American College of ... 15 – 20.  Additionally, long-term efficacy data from the ...
... technology world moves to Basking Ridge, NJ when " 2010 ... Agency (KOTRA), kicks off later this month. The conference is ... seeking the most innovative and creative technology in the U.S. ... EDT (US & Canada) at the Dolce Hotels and Resorts. ...
Cached Medicine Technology:UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 2UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 3UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 4UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 5UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 6UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 7UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 8UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 9UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 10UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease 11Top U.S. and Korean Companies to Converge at 2010 Global Partnering Day 2
(Date:7/11/2014)... 2014 AngelWeddingDress is now providing worldwide ... summer collections ”. When it comes to buying summer ... AngelWeddingDress with the unlimited stock of beautiful wedding gowns. ... its wonderful summer wedding gowns. , The company’s ... to keep pace with the newest fashion trends. The ...
(Date:7/11/2014)... American Farmer is proud to announce ... 15, 2014, at 8:30 am ET. , In this ... which are designed and formulated for use on a ... these products help the crop realize its maximum genetic ... grown. , The show also features UniSouth Genetics, a ...
(Date:7/11/2014)... 11, 2014 Alliance Labs announced that ... Innovations with Ed Begley Jr, airing later this year ... , In this episode, Innovations will explore DocuSol® Kids, ... sodium in polyethylene glycol base designed to give adolescents ... formulation functions as a hyperosmotic laxative by drawing water ...
(Date:7/11/2014)... 11, 2014 College athletes experiencing in-season ... of injury, but developed recurrent instability in 63% of ... Orthopaedic Society for Sports Medicine’s ( AOSSM ) Annual ... in providing the most optimal treatment plans for injured ... anterior shoulder instability event, and found that 33 (73%) ...
(Date:7/11/2014)... Anterior Cruciate Ligament (ACL) reconstructions occur more ... material used to create a new ligament may determine ... presenting their work today at the Annual Meeting of ... ). , “Our study results highlight that ... a donor) fail more frequently than using autografts (tissue ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Will Continuously Unveil More Summer Wedding Dresses for Loyal Clients 2Health News:New Episode of American Farmer Featuring Sunbelt, UniSouth Genetics, and Michigan Milk Producers Association Airing on RFD-TV 2Health News:Alliance Labs & DocuSol® to be Featured in Upcoming Episode of Innovations 2Health News:Intercollegiate Contact Athletes with Shoulder Instability Return to In-Season Sports, Study Shows 2Health News:ACL Reconstructions May Last Longer With Autografts 2
... workers in the United States has risen, so has ... ,According to Vanderbilt infectious disease experts Timothy R. ... be provided to health care workers with latent TB ... particularly if they meet certain high-risk criteria. ...
... researchers has discovered a new protein called as P2 ... epithelial cells// that regulates the allergic airway inflammation. ... study that the adipocyte/macrophage fatty acid–binding protein aP2, which ... of fatty acids and has been previously linked to ...
... the open access journal Substance Abuse Treatment, Prevention and policy ... training treats the alcohol dependent patients better for a long ... by trained GPs who abstain from drinking alcohol is more ... basic training alone at the medical school. Also the ...
... duvets used by most Britons are packed with dust mites, fungus ... duvets it was found to contain up to 20,000 live house ... analysis of an 11-year unwashed duvet revealed over an ounce and ... faeces. ,In addition it was found that more than ...
... new research, the risk of heart diseases is reduced on ... the University of Bristol in the UK and colleagues conducted ... between 44 to 65, and found a direct association between ... of the thickness of blood vessel walls that is used ...
... Danish researchers, in their new studies have concluded that ... suffer from a serious heart condition when compared to ... ,Research by Kirsten Melgaard Nielsen, Ph.D., and colleagues, of ... after obtaining data on 138,000 adults between the ages ...
Cached Medicine News:Health News:Study Says - Blocking 'aP2' Protein Prevents Airway Diseases 2Health News:Dust mites use Duvets as their Haven 2Health News:Long Legs Reduces The Chances Of Heart Disease 2Health News:Significant Increase In Heart Diseases Found In Older People Living Alone 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: